Research & Development
Lipum has identified a unique target for treatment of chronic inflammatory diseases. It is a protein denoted bile salt-stimulated lipase (BSSL). BSSL acts by promoting recruitment of inflammatory cells to the site of inflammation, which in the acute phase helps to control the inflammation, but in the chronic phase will sustain inflammation.
Lipum has developed a monoclonal antibody that prevents this effect of BSSL. With this novel treatment Lipum has the potential to help millions of patients who, due to chronic inflammatory diseases, suffer from a broad array of negative health consequences, including organ failures and life-long debilitation severely impairing their quality of life, and thus causing significant societal and economic burden beyond direct medical costs.